CN102573917B - 聚乙二醇化的l-天冬酰胺酶 - Google Patents

聚乙二醇化的l-天冬酰胺酶 Download PDF

Info

Publication number
CN102573917B
CN102573917B CN201080030392.6A CN201080030392A CN102573917B CN 102573917 B CN102573917 B CN 102573917B CN 201080030392 A CN201080030392 A CN 201080030392A CN 102573917 B CN102573917 B CN 102573917B
Authority
CN
China
Prior art keywords
asparaginase
conjugate
peg
erwinia
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080030392.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102573917A (zh
Inventor
T·阿布里巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals PLC
Original Assignee
Alize Pharma 2 SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alize Pharma 2 SAS filed Critical Alize Pharma 2 SAS
Publication of CN102573917A publication Critical patent/CN102573917A/zh
Application granted granted Critical
Publication of CN102573917B publication Critical patent/CN102573917B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201080030392.6A 2009-07-06 2010-07-06 聚乙二醇化的l-天冬酰胺酶 Active CN102573917B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22332009P 2009-07-06 2009-07-06
US61/223,320 2009-07-06
EPPCT/EP2010/054156 2010-03-30
PCT/EP2010/054156 WO2011003633A1 (en) 2009-07-06 2010-03-30 Pegylated l-asparaginase
PCT/EP2010/059599 WO2011003886A1 (en) 2009-07-06 2010-07-06 Pegylated l-asparaginase

Publications (2)

Publication Number Publication Date
CN102573917A CN102573917A (zh) 2012-07-11
CN102573917B true CN102573917B (zh) 2015-06-17

Family

ID=42232655

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080030392.6A Active CN102573917B (zh) 2009-07-06 2010-07-06 聚乙二醇化的l-天冬酰胺酶

Country Status (25)

Country Link
US (6) US20120100121A1 (https=)
JP (1) JP6014956B2 (https=)
KR (1) KR101731999B1 (https=)
CN (1) CN102573917B (https=)
AU (1) AU2010270294B2 (https=)
BR (1) BR112012000367A2 (https=)
CA (1) CA2767149C (https=)
CO (1) CO6612174A2 (https=)
DK (1) DK2451486T4 (https=)
EA (1) EA021168B1 (https=)
ES (1) ES2636476T5 (https=)
FI (1) FI2451486T4 (https=)
HU (1) HUE035771T2 (https=)
IL (1) IL217392A (https=)
IN (1) IN2012DN00958A (https=)
LT (1) LT2451486T (https=)
MA (1) MA33503B1 (https=)
MX (1) MX2012000424A (https=)
MY (1) MY180758A (https=)
NZ (1) NZ597912A (https=)
PE (2) PE20120501A1 (https=)
PT (1) PT2451486T (https=)
SG (1) SG176984A1 (https=)
UA (1) UA104634C2 (https=)
WO (2) WO2011003633A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE531779C2 (sv) * 2007-11-26 2009-08-04 Promimic Ab Framställning av kalciumfosfatpartiklar i nanostorlek som pulver eller beläggning via bifunktionella prekursorer
WO2011003633A1 (en) * 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015038639A1 (en) * 2013-09-10 2015-03-19 Sandia Corporation Therapeutic asparaginases
CN104046600B (zh) * 2013-12-30 2019-04-05 江苏众红生物工程创药研究院有限公司 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用
BR102014000585B1 (pt) 2014-01-10 2021-01-12 Coppe/Ufrj-Instituto Alberto Luiz Coimbra De Pós-Graduação l-asparaginase recombinante de zymomonas
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
CN105802948B (zh) 2014-12-29 2020-06-09 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
WO2017055484A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of lymphomas
EP3423480A1 (en) * 2016-03-01 2019-01-09 The Board of Trustees of the University of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
KR102783452B1 (ko) * 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP3535386A4 (en) * 2016-11-04 2020-04-15 Georgia State University Research Foundation, Inc. ENDOTOXIN-FREE ASPARAGINASE
IL271504B2 (en) * 2017-06-21 2024-05-01 Jazz Pharmaceuticals Ireland Ltd Modified l-asparaginase
EP3418383A1 (en) * 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
JP7784804B2 (ja) * 2017-10-27 2025-12-12 フェネックス インク． 組み換えｅｒｗｉｎｉａアスパラギナーゼの製造のための方法
WO2019083794A1 (en) 2017-10-27 2019-05-02 Pfenex Inc. PROCESS FOR PRODUCING EAR ASPARAGINASE. RECOMBINED COLI
JP2021505661A (ja) * 2017-11-30 2021-02-18 ジャズ ファーマシューティカルズ アイルランド リミテッド アスパラギナーゼを用いた治療法
JP2021520828A (ja) * 2018-04-19 2021-08-26 キンドレッド バイオサイエンシズ インコーポレイテッド 医療用の変異体アスパラギナーゼポリペプチド
US20210299233A1 (en) 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer
EP3867369A4 (en) * 2018-12-24 2022-09-14 Gennova Biopharmaceuticals Limited LYOPHILIZED PEGASPARGASE COMPOSITION
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
GB201912020D0 (en) * 2019-08-21 2019-10-02 Porton Biopharma Ltd Therapeutic Conjugate
JP2022553399A (ja) * 2019-10-25 2022-12-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 組換えｌ－アスパラギナーゼ
KR102269634B1 (ko) * 2019-10-31 2021-06-25 대상 주식회사 ansB 유전자 불활성화에 의해 아미노산 생산능력이 향상된 균주
US20220227805A1 (en) 2020-12-23 2022-07-21 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
CN114854729B (zh) * 2021-02-03 2025-09-02 重庆派金生物科技有限公司 定向化学偶联门冬酰胺酶突变体及其制备方法和应用
WO2022211829A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
EP4551216A1 (en) 2022-07-04 2025-05-14 Institut National de la Santé et de la Recherche Médicale Use of a l-asparaginase in combination with a ferroptosis inducer for the treatment of extranodal natural killer/t-cell lymphoma
WO2024015529A2 (en) 2022-07-14 2024-01-18 Jazz Pharmaceuticals Ireland Ltd. Combination therapies involving l-asparaginase
WO2024211977A1 (pt) * 2023-04-12 2024-10-17 Biobreyer Pesquisa E Desenvolvimento Científico Ltda Processo de peguilação sítio específica de lasparaginase contendo cisteínas de superfície, produto obtido por processo e uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018742A2 (en) * 2001-08-22 2003-03-06 Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Rossiiskoy Akademii Meditsinskikh Nauk Recombinant l-asparaginase erwinia caratovora

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5776746A (en) 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
KR20060003862A (ko) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. 수용성분기폴리머 및 그 접합체
US7985548B2 (en) 2006-03-03 2011-07-26 The United States Of America As Represented By The Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP2011639A4 (en) 2006-04-21 2012-03-07 Konica Minolta Holdings Inc GASSPERRFILM, HARZBASIS FOR ELECTROLUMINESCENCE DEVICE, THIS USING ELECTROLUMINESCENCE DEVICE AND METHOD FOR PRODUCING A GASPERRFILM
US7666652B2 (en) * 2007-03-09 2010-02-23 Novozymes A/S Asparaginases
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018742A2 (en) * 2001-08-22 2003-03-06 Gosudarstvennoe Uchrezhdenie Nauchno-Issledovatelsky Institut Biomeditsinskoy Khimii Im. Orekhovicha Rossiiskoy Akademii Meditsinskikh Nauk Recombinant l-asparaginase erwinia caratovora

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chemistry for peptide and protein PEGylation;ROBERTS M J et al.;《ADVANCED DRUG DELIVERY REVIEWS》;20020617;第54卷(第4期);459-476 *
E•coli L-天冬酰胺酶B细胞抗原表位氨基酸残基Lys~(196)对其抗原性的影响;陈建华等;《中国药科大学学报》;20061231;第37卷(第3期);277-280 *
Modification of recombinant asparaginase from Erwinia carotovora with polyethylene glycol 5000;A.V.KUCHUMOVA et al.;《BIOCHEMISTRY (MOSCOW) SUPPLEMENTAL SERIES B:BIOMEDICAL CHEMISTRY》;20070904;第1卷(第3期);230-232 *
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past,the present and recommendations for the future;AVRAMIS VASSILIOS I et al.;《CLINICAL PHARMACOKINETICS》;20050401;第44卷(第4期);367-393 *
聚乙二醇对大肠杆菌L-天冬酰胺酶的化学修饰;周笑艳等;《中国药科大学学报》;20001231;第31卷(第3期);230-233 *
蛋白质和多肽类药物的聚乙二醇结合物—一种新型给药系统;印春华等;《中国药学杂志》;20010531;第36卷(第5期);292-296 *

Also Published As

Publication number Publication date
MA33503B1 (fr) 2012-08-01
US20200347374A1 (en) 2020-11-05
CN102573917A (zh) 2012-07-11
MX2012000424A (es) 2012-07-23
USRE49736E1 (en) 2023-11-28
DK2451486T3 (en) 2017-08-28
AU2010270294B2 (en) 2015-06-25
JP6014956B2 (ja) 2016-10-26
CA2767149C (en) 2019-11-26
IL217392A0 (en) 2012-02-29
FI2451486T4 (fi) 2023-04-25
US20120100121A1 (en) 2012-04-26
KR101731999B1 (ko) 2017-05-11
PT2451486T (pt) 2017-08-09
NZ597912A (en) 2014-01-31
BR112012000367A2 (pt) 2018-01-02
WO2011003886A1 (en) 2011-01-13
US9920311B2 (en) 2018-03-20
HK1173092A1 (zh) 2013-05-10
US11046946B2 (en) 2021-06-29
ES2636476T3 (es) 2017-10-05
UA104634C2 (xx) 2014-02-25
PE20161325A1 (es) 2016-12-30
HUE035771T2 (en) 2018-05-28
CA2767149A1 (en) 2011-01-13
US12441992B2 (en) 2025-10-14
EA021168B1 (ru) 2015-04-30
IL217392A (en) 2017-06-29
US20160060613A1 (en) 2016-03-03
CO6612174A2 (es) 2013-02-01
MY180758A (en) 2020-12-08
PE20120501A1 (es) 2012-05-31
DK2451486T4 (da) 2023-04-17
EA201270134A1 (ru) 2012-07-30
US20180346900A1 (en) 2018-12-06
JP2012532185A (ja) 2012-12-13
WO2011003633A1 (en) 2011-01-13
LT2451486T (lt) 2017-11-10
SG176984A1 (en) 2012-01-30
ES2636476T5 (es) 2023-06-01
US20210348151A1 (en) 2021-11-11
IN2012DN00958A (https=) 2015-04-10
AU2010270294A1 (en) 2012-02-23
KR20120104154A (ko) 2012-09-20

Similar Documents

Publication Publication Date Title
CN102573917B (zh) 聚乙二醇化的l-天冬酰胺酶
EP2451486B1 (en) Pegylated l-asparaginase
US11802279B2 (en) Modified L-asparaginase
EP3642340B1 (en) Modified l-asparaginase
JP2024069234A (ja) アスパラギナーゼを用いた治療法
EP3418383A1 (en) Modified l-asparaginase
WO2016106941A1 (zh) 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用
HK1173092B (en) Pegylated l-asparaginase
HK40090811A (en) Modified l-asparaginase
HK40029594A (en) Modified l-asparaginase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1173092

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1173092

Country of ref document: HK